Baseline characteristics of the cancer and comparison cohorts, Denmark, 1997-2017
| . | Cancer cohort, N = 499 092 . | Comparison cohort, N = 1 497 276 . |
|---|---|---|
| Female, n (%) | 253 745 (50.8) | 761 235 (50.8) |
| Age, median (IQR), y | 68 (59-76) | 68 (59-76) |
| Age, y | ||
| <50 | 54 380 (10.9) | 163 140 (10.9) |
| 50-59 | 77 578 (15.5) | 232 734 (15.5) |
| 60-69 | 140 134 (28.1) | 420 402 (28.1) |
| 70-79 | 142 131 (28.5) | 426 393 (28.5) |
| ≥80 | 84 869 (17.0) | 254 607 (17.0) |
| Year of cancer diagnosis/index date, n (%) | ||
| 1997-2003 | 137 581 (27.6) | 412 743 (27.6) |
| 2004-2010 | 170 938 (34.2) | 512 814 (34.2) |
| 2011-2017 | 190 573 (38.2) | 571 719 (38.2) |
| Cancer stage at diagnosis, n (%)* | ||
| Localized | 172 350 (36.1) | — |
| Regional | 123 314 (25.8) | — |
| Distant | 98 919 (20.7) | — |
| Unknown | 82 975 (17.4) | — |
| Cancer treatment, n (%)† | ||
| No treatment | 109 130 (21.9) | — |
| Hormone therapy | 44 532 (8.9) | — |
| Surgery | 294 392 (59.0) | — |
| Radiotherapy | 83 107 (16.7) | — |
| Chemotherapy | 136 199 (27.3) | — |
| Targeted therapy | 21 161 (4.2) | |
| Protein kinase inhibitors | 3 088 (0.6) | |
| Antiangiogenic therapy | 4 937 (1.0) | |
| Immunotherapy | 1 775 (0.4) | |
| Other targeted therapy | 13 638 (2.7) | |
| Charlson Comorbidity Index score, n (%) | ||
| 0 | 386 018 (77.3) | 1 198 086 (80.0) |
| 1 | 84 672 (17.0) | 229 346 (15.3) |
| 2 | 20 669 (4.1) | 52 717 (3.5) |
| 3+ | 7 733 (1.5) | 17 127 (1.1) |
| Previous VTE, n (%) | 17 068 (3.4) | 36 315 (2.4) |
| . | Cancer cohort, N = 499 092 . | Comparison cohort, N = 1 497 276 . |
|---|---|---|
| Female, n (%) | 253 745 (50.8) | 761 235 (50.8) |
| Age, median (IQR), y | 68 (59-76) | 68 (59-76) |
| Age, y | ||
| <50 | 54 380 (10.9) | 163 140 (10.9) |
| 50-59 | 77 578 (15.5) | 232 734 (15.5) |
| 60-69 | 140 134 (28.1) | 420 402 (28.1) |
| 70-79 | 142 131 (28.5) | 426 393 (28.5) |
| ≥80 | 84 869 (17.0) | 254 607 (17.0) |
| Year of cancer diagnosis/index date, n (%) | ||
| 1997-2003 | 137 581 (27.6) | 412 743 (27.6) |
| 2004-2010 | 170 938 (34.2) | 512 814 (34.2) |
| 2011-2017 | 190 573 (38.2) | 571 719 (38.2) |
| Cancer stage at diagnosis, n (%)* | ||
| Localized | 172 350 (36.1) | — |
| Regional | 123 314 (25.8) | — |
| Distant | 98 919 (20.7) | — |
| Unknown | 82 975 (17.4) | — |
| Cancer treatment, n (%)† | ||
| No treatment | 109 130 (21.9) | — |
| Hormone therapy | 44 532 (8.9) | — |
| Surgery | 294 392 (59.0) | — |
| Radiotherapy | 83 107 (16.7) | — |
| Chemotherapy | 136 199 (27.3) | — |
| Targeted therapy | 21 161 (4.2) | |
| Protein kinase inhibitors | 3 088 (0.6) | |
| Antiangiogenic therapy | 4 937 (1.0) | |
| Immunotherapy | 1 775 (0.4) | |
| Other targeted therapy | 13 638 (2.7) | |
| Charlson Comorbidity Index score, n (%) | ||
| 0 | 386 018 (77.3) | 1 198 086 (80.0) |
| 1 | 84 672 (17.0) | 229 346 (15.3) |
| 2 | 20 669 (4.1) | 52 717 (3.5) |
| 3+ | 7 733 (1.5) | 17 127 (1.1) |
| Previous VTE, n (%) | 17 068 (3.4) | 36 315 (2.4) |